CSPC Pharmaceutical GroupCSPCY +9.11%74 Return-on-Tangible-Equity is 4.92% as of Dec. 2025, which is 78% below its 10-year median of 22.33. GuruFocus rates CSPCY with a GF Scoreâ„¢ of 74/100 and a GF Valueâ„¢ of $3.36 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 897 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks better than 59.53% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CSPC Pharmaceutical Group's annualized net income for the quarter that ended in Dec. 2025 was $211 Mil. CSPC Pharmaceutical Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $4,283 Mil. Therefore, CSPC Pharmaceutical Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 4.92%.
The historical rank and industry rank for CSPC Pharmaceutical Group's Return-on-Tangible-Equity or its related term are showing as below:
CSPCY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.05 Med: 22.33 Max: 27.33
Current: 11.05
During the past 13 years, CSPC Pharmaceutical Group's highest Return-on-Tangible-Equity was 27.33%. The lowest was 11.05%. And the median was 22.33%.
CSPCY's Return-on-Tangible-Equity is ranked better than 59.53% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs CSPCY: 11.05
CSPC Pharmaceutical Group (OTCPK:CSPCY) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
CSPC Pharmaceutical Group Return-on-Tangible-Equity Related Terms
CSPC Pharmaceutical Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for CSPC Pharmaceutical Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group Return-on-Tangible-Equity Chart
CSPCY vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.92% mean?
CSPC Pharmaceutical Group (CSPCY) has a Return-on-Tangible-Equity of 4.92% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CSPC Pharmaceutical Group and its competitors. This is 78% below median its historical median of 22.33. Over the past decade, CSPC Pharmaceutical Group's Return-on-Tangible-Equity has ranged from 11.05 to 27.33. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #363 out of 897 companies in the Drug Manufacturers industry, placing it in the top 40.5%.
Is CSPC Pharmaceutical Group's Return-on-Tangible-Equity too high?
CSPC Pharmaceutical Group's current Return-on-Tangible-Equity of 4.92% is 78% below median its 10-year median of 22.33. Over the past 10 years, this metric has ranged from a low of 11.05 to a high of 27.33. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. CSPC Pharmaceutical Group's value of 4.92% is 37.7% below this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #363 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Scoreâ„¢ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #363 out of 897 companies for Return-on-Tangible-Equity. This puts CSPC Pharmaceutical Group in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. CSPC Pharmaceutical Group's value of 4.92% is 37.7% below this benchmark. Historically, CSPC Pharmaceutical Group's own Return-on-Tangible-Equity has ranged from 11.05 to 27.33 over the past decade. While the company's 10-year median is 22.33 vs. the industry median of 7.90, CSPC Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current Return-on-Tangible-Equity of 4.92% is 37.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CSPC Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current Return-on-Tangible-Equity is 4.92%, which is 78% below median its own 10-year median of 22.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.36, compared to a current price of $4.19 — trading 24.7% above its estimated fair value. The current Return-on-Tangible-Equity is 4.92%, which is 78% below median its 10-year median of 22.33 and 37.7% below the Drug Manufacturers industry median of 7.90. CSPC Pharmaceutical Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current Return-on-Tangible-Equity is 4.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $4.19 is trading 24.7% above its estimated GF Value™ of $3.36.
GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for CSPCY:
Return-on-Tangible-Equity: 4.92% (78% below median its 10-year median of 22.33)
GF Value™: $3.36 vs. price of $4.19 (24.7% above fair value)
Industry Position: 37.7% below the Drug Manufacturers median (#363 of 897)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
74GF Score
Get the complete analysis for CSPCY
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
